CAMBRIDGE

Cambridge University Press
978-1-107-04131-8 - Androgens in Gynecological Practice
Edited by Leo Plouffe and Botros R. M. B. Rizk
Index
More information

Index

ABCC11 gene, 82
abdominal obesity, 6
abdominal phenotype, 209
acanthosis nigricans, 6, 19, 28, 122
  in PCOS, 164–165
acetazolamide, 172
acne, 82–84
  diagnosis, 82
  in PCOS, 163
  treatment, 33–34, 83
acrochordon, *see* skin tags
acromegaly, 29, 30
  differential diagnosis, 172
ACTH, 111, 118, 180
  Cushing's syndrome, 127–129
  ectopic ACTH syndrome, 119
  excess, 118
ACTH stimulation test, 6, 114
adipocytes, metabolic role, 210
adipocytokines, 210, 212
adipokines, 91
adiponectin, 91
adrenal aging, 200
adrenal disorders, 119–120
  hematoma, 197
  PPNAD, 120
  tumors, *see* adrenal tumors
adrenal MRI, 191–199
  inversion recovery fat suppression, 193
  lipid detection techniques, 191–193
    chemical shift imaging, 191–192
    CHESS, 192–193
  normal adrenal glands, 195
  post-contrast images, 194
  T1-weighted images, 194
  T2-weighted images, 193–194
  see also adrenal disorders, adrenal tumors
adrenal tumors, 29
  adenoma, 195–196
  adrenocortical carcinoma, 198
  and hirsutism, 4, 18
  metastatic disease, 196
  myelolipoma, 196–197
  pheochromocytoma, 197
adrenalectomy, 116, 130, 131–132
adrenocorticotropic hormone, *see* ACTH
adult granulosa cell tumor, 139–141
advanced glycation end products, 92, 212
Aging Male Symptoms (AMS) score, 155
alopecia, 11–24
  androgenetic, 12, 84–85
  female pattern hair loss, *see* female pattern hair loss
  in PCOS, 164
alopecia areata, 14
amenorrhea, 6, 104, 165
  differential diagnosis, 172
  see also PCOS
American Society for Reproductive Medicine (ASRM), 74, 89
aminoglutethimide, 130, 131
anabolic steroids, 157
anastrozole, 32
androblastomas, *see* Sertoli-stromal cell tumors
AndroFeme, *see* transdermal testosterone patch
AndroGel system, 43
androgens, 180
  anabolic effects, 201
  and hair growth, 11–12
  deficiency/excess, *see* androgen deficiency, androgen excess
  extraovarian, 65
  genital tract effects, 109
    development and differentiation, 97–99
    structure and function, 99–103
  metabolism, 1
  ovarian production, 67–69
  in postmenopausal women, 64–74, 105, 106, 200–207
    bone, 201
    breast, 203–205
    endometrium, 202–203
    muscle and lean body mass, 201–202
    quality of life, 202
  skin effects, 79–82
    hair follicles, 81
    sebaceous glands, 81
    sweat glands, 81–82
  skin metabolism, 80–81
  skin-related, 79
  see also individual hormones
androgen antagonists, *see* antiandrogens
androgen assays, 180–190
  clinical use, 184–185
  in vitro, 182–183
  in vivo, 181
    immunoassay, 181–182, 185–188
    mass spectrometry, 182
  testosterone
    free, 184
    total, 183–184
    see also individual assays
androgen deficiency, 38, 39, 41, 104–106
  men, 152–153
    patient-reported outcome tools, 155–156
  premenopausal women, 104
    idiopathic, 105
    oral contraceptives, 104
  treatment, *see* testosterone replacement therapy
Androgen Deficiency of Aging Men (ADAM) questionnaire, 155
androgen destabilizers, 61
androgen excess, 1, 14, 19, 26, 29, 34, 83, 85, 89, 103–104, 136, 209
  diagnosis, 75
  drugs causing, 172
  etiology, 5
  family history, 6
  gestational, 6
  idiopathic, 4
  and PCOS, 209
  see also congenital adrenal hyperplasia, PCOS
Androgen Excess and Polycystic Ovary Syndrome Society, 1
Androgen Excess Society (AES), 74, 89
androgen exposure
  levels of, 71
  markers of, 69–71
androgen insensitivity syndrome, *see* complete androgen insensitivity syndrome (CAIS)
androgen metabolites, 69–71
androgen receptors, 55–63, 79–80, 200
  agonists, 56, 57, 61
  antagonists, *see* antiandrogens

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-04131-8 - Androgens in Gynecological Practice
Edited by Leo Plouffe and Botros R. M. B. Rizk
Index
More information

androgen receptors (*cont.*)
bone, 201
co-activators and co-repressors, 58–59
historical context, 55
inactive state, 57
ligand binding and activation, 57–58
molecular disorders linked to, 59–60
androgen insensitivity syndrome, 59–60
breast cancer, 60
Kennedy disease, 60
partial agonists, 61
structure, 55–57
ligand-binding domain, 56
therapeutic interventions, 60–61
androgen replacement therapy, *see* testosterone replacement therapy
androgen response elements, 58
androgen-producing ovarian tumors, 136–145
classification, 139
diagnosis, 137–139
interventional testing, 138
laboratory tests, 137
radiology, 137–138
embryology, 139
history and examination, 136–137
idiopathic, 143
pregnancy-associated, 143
treatment, 143–144
androgen-related skin disorders, 82–87
acne, 82–84, 163–164
androgenetic alopecia, 12, 84–85
hidradenitis suppurativa, 86
hirsutism, *see* hirsutism
androgen-secreting tumors, 6
androgenetic alopecia, 12, 84–85
diagnosis, 84
treatment, 85
androgenic compounds, 57
androstenedione, 11, 29, 42, 79, 118, 180
normal range, 105
anorgasmia, 40
antagonists, 57
antiandrogens, 8, 56, 61
CAH, 115
FPHL, 15–16
hidradenitis suppurativa, 87
PCOS, 33
see also individual drugs
antibodies, effects on immunoassay, 186
anti-müllerian hormone, 30, 75, 98
anxiety disorders
in PCOS, 169
APHRODITE study, 204
apolipoprotein CIII, 49
apoptosis, 11
arachidonic acid, 122
arginase, 101
aromatase, 98, 204
fetal, 98
aromatase inhibitors, 32, 216, 228
PCOS, 216–217
see also individual drugs
asymmetric dimethylarginine, 92
autoantibodies, 187
aversion disorder, 38

basic fibroblast growth factor (bFGF), 118
Beckwith–Wiedemann syndrome, 198
beta-endorphin, 118
beta-lipoprotein, 118
bicalutamide, 61
bilateral inferior petrosal sinus sampling, 129
bleaching of hair, 7
BLISS study, 204
body mass index (BMI), 19, 26, 209
bone
androgen effects, 201
androgen receptors in, 201
mass, 154
mineral density (BMD), 154
Boston Area Community Health (BACH) Survey, 153
breast
androgen effects, 203–205
Tanner staging, 28
breast cancer
androgen receptor role in, 60, 205
and androgen replacement therapy, 45, 204
PCOS, 171
"buffalo hump" of Cushing's syndrome, 121

CA 19-9, 187
CAH, *see* congenital adrenal hyperplasia
camouflage for hair loss, 17
cardiovascular risks
androgen replacement therapy, 45–49
PCOS, 89–96, 168
Carney complex, 123, 198
carotid intima–media thickness, 92
cell proliferation assay, 183
Center for Epidemiologic Studies Depression Scale (CES-D), 202
central centrifugal cicatricial alopecia, 14
chaperone proteins, 57
chemerin, 92
chemical shift imaging (CSI), 191–192
chemical shift selective suppression, *see* CHESS
CHESS, 191, 192–193
chlormadinone acetate, 8, 86
clitoris, 98
androgen effects, 99–100
clitoromegaly, 6, 19, 28
clomiphene citrate, 31, 220
mechanism of action, 227
with metformin, 219
PCOS, 216
ovulation induction, 227–228
resistance, 32
side effects, 217
co-chaperone proteins, 57
cognitive-behavioral impact of androgen disorders, 146–150
complete androgen insensitivity syndrome (CAIS), 59–60, 98, 146
cognitive-behavioral impact, 147
gender identity/role, 147
mental health status, 148
computed tomography (CT) of androgen-producing ovarian tumors, 137
congenital adrenal hyperplasia, 6, 13, 85, 103, 111–117, 146
clinical presentation, 113
cognitive-behavioral impact, 147
diagnosis, 114–115
hormonal, 114
molecular genetics, 114–115
newborn screening, 115
gender identity/role, 147
hirsutism, 18
21-hydroxylase deficiency, *see* 21-hydroxylase deficiency
late onset, 29
mental health status, 148
pathophysiology, 111–113
pregnancy, 116
treatment, 115–116
medical, 115
prenatal, 116
surgical, 115–116
visuo-spatial processing, 147
Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE), 115
coronary heart disease, 92
corticotropin stimulation test, 114
corticotropin-releasing hormone (CRH), 112, 118
ectopic CRH syndrome, 119
corticotropin-releasing hormone stimulation test, 129
cortisol, 112
anabolic effects, 121
excess, 118, 122, 123, 136
diagnosis, 123–127
see also Cushing's syndrome
late-night salivary, 126
midnight serum, 127
urinary free, 124–126
cosyntropin, 172
cranial prosthesis, 17
C-reactive protein, 92
CRH, *see* corticotropin-releasing hormone
CT, *see* computed tomography
Cushing, Harvey, 119
Cushingoid habitus, 121

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-04131-8 - Androgens in Gynecological Practice
Edited by Leo Plouffe and Botros R. M. B. Rizk
Index
More information

Cushing's disease, 119
Cushing's syndrome, 19, 26, 29, 85, 89, 118–135
  biochemical testing, 123–129
    ACTH dependence, 127
    ACTH source, 127–129
    cortisol excess, 123–127
  clinical presentation, 120–122
    hirsutism, 18
  diagnosis, 123–124
  differential diagnosis, 122, 123, 172
  epidemiology, 120
  etiology, 118–119
    adrenal disorders, 119–120
    ectopic ACTH syndrome, 119
    ectopic CRH syndrome, 119
    glucocorticoid therapy, 115
    iatrogenic, 119, 122, 129
    McCune–Albright syndrome, 120
    PPNAD, 120
  female predominance, 120
  morbidity and mortality, 122
  pathophysiology, 118
  screening for, 30
  treatment, 129–132
    ACTH-dependent Cushing's syndrome, 130–132
    ACTH-independent Cushing's syndrome, 130
    iatrogenic Cushing's syndrome, 129
cyclosporin, 19, 172
cyclosporin A-binding protein (Cyp40), 57
CYP11A, 69
CYP17, 69
CYP19, 69
CYP19A1, 98
CYP21A2, 111
cyproterone acetate, 8, 20, 61
  acne vulgaris, 84
  CAH, 115
  FPHL, 16
  hidradenitis suppurativa, 87
  hirsutism, 21, 86
  PCOS, 34
cystitis, 40

danazol, 18, 19, 172
dehydroepiandrosterone, *see* DHEA
dehydroepiandrosterone sulfate, *see* DHEA-S
11-deoxycorticosterone, 118
depilatory agents, 7, 21
desogestrel, 8
dexamethasone, 115
dexamethasone suppression test, 30, 126–127
  1 mg overnight, 126
  2 mg/day 48-hour low-dose, 126
  2 mg/day 48-hour low-dose with CRH, 127
  high-dose, 128–129
DHEA, 11, 42, 64, 79, 98, 180
  circulating levels, 67–69, 70
  postmenopause, 66–68, 106
  post-ovariectomy effects, 99
  vaginal epithelial growth, 101
DHEA-S, 11, 14, 29, 42, 79, 80, 98, 118, 180
  adrenal tumors, 29
  androgen-producing ovarian tumors, 137
  circulating levels, 68
  measurement, 20, 104
  normal range, 105
  in PCOS, 227
  postmenopausal women, 200–207
diabetes mellitus
  gestational, 170
  type 2, 89
    and PCOS, 167
    and testosterone deficiency, 154
diazoxide, 172
dietary interventions in PCOS, 212
dihydrotestosterone, 2, 11, 69, 79, 101
  female pattern hair loss, 12
  and hair growth, 12
disorders of sex development
  cognitive-behavioral impact, 146–150
  see also individual disorders
Dixon method, 192
doping agents, 183
drospirenone, 8, 20, 61
dutasteride, 16
dysgerminomas, 143
dyslipidemia, 89, 91
dyspareunia, 38, 40–41
  vaginal atrophy, 41

ectopic ACTH syndrome, 119
ectopic CRH syndrome, 119
eflornithine, 6
  hirsutism, 21, 34, 86
electroepilation, 22
electrolysis, galvanic, 7
Endogenous Hormones and Breast Cancer Collaborative Group, 204
endometrial cancer, 33
  and androgen replacement therapy, 45
  and PCOS, 31
endometrium, androgen effects, 202–203
endothelin-1, 92
enzyme regulation, androgen-mediated, 100–101
epicardial fat, 92
epidermal growth factor receptor inhibitors, 82
E-SCREEN assay, 183
estradiol, circulating levels, 221
estrogens, 61
estrogen receptor, 55, 56
estrogen replacement therapy, *see* hormone replacement therapy
ethinylestradiol, 8
  hidradenitis suppurativa, 87
etomidate, 130, 131
European Male Aging Study (EMAS), 153
European Society of Human Reproduction and Embryology (ESHRE), 74, 89
exercise, 212–213
external genitalia, 98–99

familial dysalbuminemia, 186
Favre–Racouchot syndrome, 83
FDG-PET/CT, 138
female androgen deficiency syndrome, 42, 200
female orgasmic disorder, 38, 40
female pattern hair loss, 12
  clinical features and classification, 13
  evaluation, 14
  pathogenesis, 12–13
  treatment, 15–17
    androgen-dependent therapies, 15–16
    androgen-independent therapies, 15
    see also specific drugs
female sexual differentiation, *see* sexual differentiation
female sexual dysfunction, *see* sexual dysfunction
Ferriman–Gallwey score, modified, 2, 4, 17, 19, 26, 163
fibrinogen, 92
fibroblast growth factor receptor 2 (FGFR2), 82
fibrosing alopecia, 14
finasteride, 8
  androgenetic alopecia, 85
  CAH, 115
  FPHL, 16
  hirsutism, 21, 86
  PCOS, 34
FK506-binding proteins, 57, 58
9α-fludrocortisone acetate, 115
fluorine-18-deoxyglucose positron emission tomography/computed tomography, *see* FDG-PET/CT
flutamide, 8, 61
  acne vulgaris, 83
  CAH, 115
  FPHL, 16
  hirsutism, 21, 33, 86
foldosome, 57, 58
follicle-stimulating hormone, *see* FSH
follicular miniaturization, 84
follicular unit transplantation, 17
FPHL, *see* female pattern hair loss
frailty, 154
free androgen index (FAI), 44, 184, 202
free testosterone, 184
FSH, 30, 180, 219, 226

gel filtration chromatography, 188
gender identity, 146

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-04131-8 - Androgens in Gynecological Practice
Edited by Leo Plouffe and Botros R. M. B. Rizk
Index
More information

gender role, 146
genital tract, androgen effects, 97–109
  development and differentiation, 97–99
  structure and function, 99–103
    clitoris and vagina, 99–100
    sexual arousal response, 101–103
    vasomotor and trophic enzyme regulation, 100–101
germ cell tumors, 139, 143
gestational diabetes mellitus, 170
gestodene, 8
glucocorticoids, 18, 19, 115
  hypertrichosis, 172
glucose tolerance test, 6
GnRH agonists, 230
gonadotropins, 219–222
  indications, 220–221
  monitoring and administration, 221–222
  ovarian hyperstimulation syndrome, *see* ovarian hyperstimulation syndrome
  ovulation induction, 229–230
  preparations, 220
  see also individual hormones
gonadotropin-releasing hormone, *see* GnRH agonists
granulosa cell tumors (GCT), 140
  adult, 139–141
  juvenile, 141
guanylyl cyclase, 101
gynecomastia, 60

hair follicles, androgen effects, 81
hair growth, 1, 2
  anagen phase, 11
  catagen phase, 11
  physiology, 11
  sex steroid effects, 11–12
  telogen phase, 11
hair transplantation, 16
Hamilton–Norwood classification of FPHL, 14
hCG, 188, 219
HDL cholesterol, 91
health-related quality of life scale (HRQOL), 202
heat shock proteins, 57, 79
  see also specific proteins
hemolysis, effect on androgen assay, 186
heterodimers, 58
hidradenitis suppurativa, 86–87
  diagnosis, 86
  treatment, 87
high-dose dexamethasone suppression test, 128–129
HIP, 57
hirsutism, 1–10, 17, 148, 174
  diagnosis, 4–6, 85
  epidemiology, 2–4
  etiology, 17–19
    adrenal tumors, 18
    androgen-related, 85–86
    congenital adrenal hyperplasia, 18, 85
    Cushing's syndrome, 18
    hyperprolactinemia, 19
    hyperthecosis, 18
    iatrogenic, 18
    idiopathic, 1, 4, 18–19
    ovarian tumors, 18
    PCOS, 18, 162–163, 210
  evaluation, 19
  laboratory investigations, 19–20
  management, 6–8
  modified Ferriman–Gallwey score, 2, 4, 17, 19, 26, 163
  pathophysiology, 1–2
  prevalence, 2–4
  treatment, 20–22, 33–34, 86
    cosmetic, 21–22
    medical, 20–21
    see also individual drugs
hMG, 220
  PCOS treatment, 33
homocysteine, 92
homodimers, 58
HOP, 57
hormone action, mechanism of, 56
hormone replacement therapy, 151–152
  estrogen-only trial, 152
  estrogen plus progestin trial, 152
  risk–benefit ratio, 152
  see also testosterone replacement therapy
hormone response element, 56
HSDD, *see* hypoactive sexual desire disorder
HSP40, 57
HSP56, 79
HSP70, 57, 79
HSP90, 57, 58, 79
human anti-animal antibodies (HAAA), 187
human chorionic gonadotropin, *see* hCG
human menopausal gonadotropin, *see* HMG
hydrocortisone, 115
16-hydroxy DHEA-S, 98
17α-hydroxylase, 111
21-hydroxylase deficiency, 29, 111, 113–114
  treatment, 115
17-hydroxyprogesterone, 6, 30, 113, 114
3α-hydroxysteroid dehydrogenase, 80
3β-hydroxysteroid dehydrogenase, 80, 111
17β-hydroxysteroid dehydrogenase, 80
hyperandrogenism, *see* androgen excess
hypercortisolemia, *see* cortisol, excess
hyperinsulinemia, 209, 210, 212
hyperlipoproteinemia, 60
hyperprolactinemia, 19, 89
  differential diagnosis, 172
hypertension
  in PCOS, 91, 167
  pregnancy-induced, 171
hyperthecosis, 18, 34
hypertrichosis, 19
  drugs causing, 172
  see also hirsutism
hypertriglyceridemia, 33
hypoactive sexual desire disorder, 38, 39–40
  treatment, *see* testosterone replacement therapy
hypoandrogenism, *see* androgen deficiency
hypogonadism, 122
  men, 153–155
  symptoms and signs, 153–155
Hypogonadism in Males (HIM) study, 153
hypokalemia, 128
hypophysectomy, 130–131
hypopituitarism, 131
hypothalamic–pituitary–adrenal axis, 118

immunoadsorption chromatography, 188
immunoassay, 181–182
  interference, 185–188
    detection of, 187–188
    endogenous factors, 186–187
    exogenous factors, 185–186
  serial dilutions, 187
impaired glucose tolerance, 89
  prevalence, 89
in vitro fertilization (IVF), 33
in- and out-of-phase imaging, *see* chemical shift imaging (CSI)
incidentaloma, 127
inferior petrosal sinus sampling, bilateral, 129
infertility, 6, 208
  PCOS, 25, 170, 218
inocoterone, 84
insulin resistance, 28, 89, 90, 122, 163, 164, 209, 210
  in PCOS, 167
insulin sensitizers, 8
  hirsutism, 21
  PCOS, 229
insulin-like growth factor-1 (IGF-1), 82, 118
insulin-like growth factor-2 (IGF-2), 118
interference assays, 188
interferon-alpha, 172
International Agency for Research on Cancer (IARC), 139
INTIMATE trials, 204
intracrinology, 65, 67
Intrinsa, *see* transdermal testosterone patch
inversion recovery fat suppression, 193
isosexual pseudo-precocity, 141
isotretinoin, 84

juvenile granulosa cell tumor, 141

Kennedy disease, 60
keratosis pilaris, 83
ketoconazole, 130, 131
Krukenberg tumors, 6

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-04131-8 - Androgens in Gynecological Practice
Edited by Leo Plouffe and Botros R. M. B. Rizk
Index
More information

Ladder of Life scale, 202
lanugo hair, 11
late-night salivary cortisol, 126
LDL cholesterol, 91
lean body mass, androgen effects, 201
leptin, 91, 210, 212
letrozole, 32, 216
  ovulation induction, 228
levonorgestrel, 8, 172
Leydig cells, 139
  tumors of, 140, 142
LH, 30, 180, 219, 226
lichen sclerosis et atrophicus, 40
lifestyle interventions in PCOS, 211–213
  diet, 212
  exercise, 212–213
Li–Fraumeni syndrome, 198
ligand-binding domain, 56
lipid panel screen, 30
lipodystrophy, 28
lipoprotein(a), 92
Livensa, *see* transdermal testosterone patch
Ludwig's classification of FPHL, 13
luteinizing hormone, *see* LH
luteomas of pregnancy, 143
17,20-lyase, 111

macroprolactin, 187, 188
macroprolactinemia, 29
magnetic resonance imaging of adrenal gland, *see* adrenal MRI
mass spectrometry, 64, 182
  testosterone, 64, 184
McCune–Albright syndrome, 120
Medical Outcome Scale (MOS-SF-36), 202
melanocyte-stimulating hormone (MSH), 118
men
  androgen deficiency, 152–153
    patient-reported outcome tools, 155–156
  androgen replacement therapy, 151–160
  hypogonadism, 153–155
menopause, 151–152
  see also postmenopausal women
menopause rating scale (MRS), 202
mental health status
  PCOS, 169–170
  sex differences, 148
metabolic syndrome, 25, 26, 31, 69, 89, 90, 121
  definitions, 90
  diagnosis, 166
  and PCOS, 90, 165–166
  prevalence, 90
  and testosterone deficiency, 154
  treatment, 34–35
metformin, 21, 33, 217–219
  with clomiphene citrate, 219
  indications, 218–219
  ovulation induction, 229
  pharmacology and dosing, 217
  precautions and monitoring, 218
methyltestosterone, 43, 61
metyrapone, 130, 131, 172
midnight serum cortisol, 127
Million Women Study, 152
minocycline, 172
minoxidil, 15, 19, 85, 172
miscarriage in PCOS, 170
mitotane (o,p'-DDD), 130, 131
"moon face" of Cushing's syndrome, 121
MRI, *see* magnetic resonance imaging
MRL-41, *see* clomiphene citrate
multiple endocrine neoplasia type 1 (MEN1), 119
muscle, androgen effects, 201
myelolipoma, 196–197

Nelson's syndrome, 132
neonate
  complications of PCOS, 171
  screening for CAH, 115
neoplasms in PCOS, 171
  breast cancer, 171
  endometrial cancer, 31, 33
nitric oxide, 101
nitric oxide synthase, 101
nonalcoholic fatty liver disease, 91, 168
nonalcoholic steatohepatitis, 168
norethindrone, 172
norgestreol, 172
nuclear receptors, 56
Nurses' Health Study, 204

obesity, 91, 92, 208
  abdominal, 209
  central, 121
  in PCOS, 166–167, 208–209
    disease presentation, 210–211
    pathophysiology, 209–210
  treatment
    diet, 212
    exercise, 212–213
obstructive sleep apnea, 91
  in PCOS, 168
oligomenorrhea, 6, 165
Olsen's classification of FPHL, 13
oral contraceptives
  and androgen deficiency, 104
  androgen assay interference, 185
  estrogen-progestin, 20–21
  hirsutism, 7, 8, 18, 33
oral glucose tolerance test, 30
ovarian drilling, 228–229
ovarian hyperstimulation syndrome, 33, 220, 221
  prevention, 222
  risk factors, 221
ovarian tumors, 29
  and androgen replacement therapy, 45
  androgen-producing, 136–145
  hirsutism, 4, 18
  sex cord-stromal, *see* sex cord-stromal tumors
ovarian vein sampling, 138
ovarian wedge resection, 31, 33
ovariectomy, effects of, 99, 100, 101
ovary, androgen production by, 67–69
ovulation induction, 226–232
  clomiphene citrate, *see* clomiphene citrate
  gonadotropins, 229–230
  insulin sensitizers, 229
  letrozole, 228
  ovarian drilling, 228–229
ovulatory dysfunction in PCOS, 31–33

p23 protein, 57
P450 oxidoreductase, 111
painful intercourse, *see* dyspareunia
PCOS, *see* polycystic ovary syndrome
pelvic ultrasound, 30
penicillamine, 172
perioral dermatitis, 83
Pharmacy Compounding Accreditation Board, 44
phenothiazine, 172
phenytoin, 19, 172
pheochromocytoma, 119
  MRI, 197
photoepilation, 7, 22
pilosebaceous unit, 1
pioglitazone, 21
pituitary irradiation, 132
pituitary tumors, 119
placental aromatase deficiency, 6
plasminogen activator inhibitor-1, 92
polycystic ovary syndrome (PCOS), 2, 4, 6, 8, 13, 25–37, 104, 161–179, 208–215
  cardiovascular risk, 89–96, 168
  clomiphene-resistant, 32
  depression in, 169
  diagnosis, 26, 226
  diagnostic criteria, 74–78, 89, 162
  differential diagnosis, 171–174
  etiology, 25–26, 161
    androgen excess, 209
    psychological stress, 211
    uterine environment, 209
  evaluation, 26–28, 173
  laboratory investigations, 28–31
  lifestyle interventions, 211–213
    diet, 212
    exercise, 212–213
  neoplasms, 171
    breast cancer, 171
    endometrial cancer, 31, 33
  and obesity, 91, 92, 166–167, 208–209
    disease presentation, 210–211
    pathophysiology, 209–210

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-04131-8 - Androgens in Gynecological Practice
Edited by Leo Plouffe and Botros R. M. B. Rizk
Index
More information

polycystic ovary syndrome (PCOS) (*cont.*)
ovulation induction, 226–232
clomiphene citrate, 227–228
gonadotropins, 229–230
insulin sensitizers, 229
letrozole, 228
ovarian drilling, 228–229
phenotypes, 75, 162
physical examination, 174
pregnancy complications, 170
gestational diabetes, 170
hypertension, 171
neonatal, 171
preterm birth, 171
recurrent miscarriage, 170
prevalence, 76–77, 227
screening, 93
symptoms
acanthosis nigricans and skin tags, 164–165
acne, 163–164
alopecia, 164
cutaneous, 161–162
hirsutism, 18, 19, 85, 162–163, 210
hypertension, 91, 167
infertility, 170, 208, 218
insulin resistance, 167
metabolic syndrome, 165–166
nonalcoholic fatty liver disease, 91, 168
obstructive sleep apnea, 91, 168
ovulatory dysfunction, 165
psychiatric, 169–170
treatment, 31–35, 216–225, 227
aromatase inhibitors, 216–217
clomiphene citrate, 216
gonadotropins, 219–222
hirsutism and acne, 33–34
metformin, 217–219
ovulatory dysfunction, 31–33
see also metabolic syndrome
polymenorrhea, 165
postmenopausal women
androgen effects, 64–74, 105, 106, 200–207
bone, 201
breast, 203–205
endometrium, 202–203
muscle and lean body mass, 201–202
quality of life, 202
circulating DHEA levels, 66–69, 70, 106
PPNAD, *see* primary pigmented nodular adrenal disease
pregnancy
androgen-producing ovarian tumors, 143
and CAH, 116
luteomas of, 143
PCOS, 170
gestational diabetes, 170
hypertension, 171
neonatal complications, 171
preterm birth, 171
recurrent miscarriage, 170
Pregnancy in Polycystic Ovary Syndrome I (PPCOS I) trial, 218
premenopausal women
androgen deficiency, 104
idiopathic, 105
oral contraceptives, 104
androgen replacement therapy, 42
prenatal treatment of CAH, 116
preterm birth in PCOS, 171
Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking (PRESIDE), 38
primary pigmented nodular adrenal disease (PPNAD), 120
progesterone, 6
progesterone receptor, 55, 56
progestins, 61
withdrawal bleeding, 28
prolactin, 6
high-dose hook effect, 29
measurement, 29
pro-opiomelanocortin (POMC), 118
Propionibacterium acnes, 82, 163
protein catabolism, 122
protein kinase A, 120
pseudo-Cushing's syndrome, 30
pseudohermaphroditism in male fetuses, 8
psoralens, 172
Psychosexual Daily Questionnaire (PDQ), 155

5α-reductase, 80, 81
inhibitors, 83, 85
see also individual drugs
reporter gene assays, 183
rheumatoid factor, 187
rosacea, 83
rosiglitazone, 21, 219

SARMs, 57, 61
sclerosing stromal tumor, 141
sebaceous glands
androgen effects, 81
androgen metabolism, 79
sebaceous hyperplasia, 83
selective androgen receptor modulators. *See* SARMs
selective estrogen receptor modulators. *See* SERMs
selective venous catheterization and hormonal sampling (SVCHS), 138
SERMs, 32
Sertoli cells, 139
tumors of, 142
Sertoli–Leydig cell tumors, 141–142
Sertoli-stromal cell tumors, 140, 141–142
sex cord-stromal tumors, 139–142
adult granulosa cell tumor, 139–141
juvenile granulosa cell tumor, 141
sclerosing stromal tumor, 141
Sertoli-stromal cell tumors, 141–142
steroid cell tumors, 142
thecoma, 141
sex determination, 97
sex hormone-binding globulin, *see* SHBG
sexual abuse, 41
sexual arousal, 101–103
sexual arousal disorder, 38
sexual development, 97–99
external genitalia, 99
sexual differentiation, 97–98
sexual dysfunction, 38–53, 204
anorgasmia, 40
comorbidities, 39, 41
definition, 39
dyspareunia, 40–41
examination, 41
history, 39
HSDD, 39–40
treatment, *see* testosterone replacement therapy
sexual trauma, 41
sexually dimorphic cognitive behaviors, 146
SHBG, 1, 6, 14, 29, 33, 83, 181, 201
bound testosterone, 184
insulin effects, 209
pregnancy, 143
Sheehan's postpartum necrosis, 104
short-tau inversion recovery (STIR), 193
sialic acid, 102
sialo-glycoproteins, 102
skin
androgen effects on, 79–82
hair follicles, 81
sebaceous glands, 81
sweat glands, 81–82
androgen metabolism in, 80–81
skin disorders, androgen-related, 82–87
acne, 82–84, 163–164
androgenetic alopecia, 12, 84–85
hidradenitis suppurativa, 86–87
hirsutism. *See* hirsutism
in PCOS, 161–162
skin tags, 28
in PCOS, 164–165
skin-related androgens, 79
sleep apnea, 31
sodium valproate, *see* valproate
spinal and bulbar muscular atrophy, *see* Kennedy disease
spin-spin relaxation, 193
spironolactone, 8, 15–16, 20, 21, 33, 61
acne vulgaris, 84
hirsutism, 86
SRC proteins, 58
Stein–Leventhal syndrome, *see* polycystic ovary syndrome

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-04131-8 - Androgens in Gynecological Practice
Edited by Leo Plouffe and Botros R. M. B. Rizk
Index
More information

steroid cell tumors, 140, 142
steroidogenic acute regulatory (StAR) protein, 111
sterol-regulatory element-binding proteins (SREBPs), 82
streptomycin, 172
stress, and PCOS, 211
stromal luteoma, 140, 142
Study of Women's Health Across the Nation (SWAN) study, 202
sweat glands
  androgen effects, 81–82
  androgen metabolism, 79

telogen effluvium, 14, 84
terminal hair, 1, 11
test tubes for androgen assays, 186
testicular feminization, 98
testicular feminization syndrome, *see* androgen insensitivity syndrome
Testim 1% transdermal gel, 44
testosterone, 1, 6, 79, 180
  abuse, 157
  androgen-producing ovarian tumors, 137
  assays, *see* androgen assays
  and FPHL, 14
  free, 184
  and hair growth, 12
  and hirsutism, 18, 19
  measurement, 19, 29
    mass spectrometry, 64
  normal range, 105
  prenatal exposure, 98
  protein binding, 181
  total, 183–184
  vaginal muscular function, 103
testosterone cream, 44–45
testosterone deficiency, 154
  hypogonadism, 153–155
  and metabolic syndrome, 154
  treatment, *see* testosterone replacement therapy
testosterone patch, 43, 44
testosterone replacement therapy, 38, 42–49, 105, 153
  contraindications, 49
  health risks, 153
  lack of US FDA approval, 44
  men, 151–160
  patient monitoring, 157–158
  postmenopause, 42–43, 203
  pre- and perimenopause, 42
  pre-treatment evaluation, 156
  route of delivery, 43
  safety of, 106–107
  side effects, 45–48
    cancer, 45
    cardiovascular, 45–49
  treatment options, 43–44, 156–157
    cream, 44–45
    transdermal patch, 43, 44
    see also hormone replacement therapy
testosterone undecanoate, 43, 61
tetracosactide, 172
thecoma, 140, 141
thermolysis, 7
thrifty phenotype theory, 25
thyroid disease, differential diagnosis, 172
thyrotropin, 6
tibolone, 201
total testosterone, 183–184
transdermal testosterone patch, 43, 44, 204
transforming growth factor beta (TGFβ), 84
trans-sphenoidal microadenectomy, 130–131
tumor necrosis factor-alpha, 92
tumors, *see specific types*
type 2 diabetes mellitus, *see* diabetes mellitus, type 2

ultrasound, pelvic, 30
urethritis, 40
urinary free cortisol, 124–126

vagina
  androgen effects, 99–100
  atrophy, 41
  blood flow, 101
Vaginal Maturation Index, 28
vaginismus, 38
valproate, 172
  hirsutism, 6
vascular endothelial growth factor, 92
vasointestinal polypeptide, 103
vellus hair, 1, 11
virilization, 6, 19, 28, 137
virilizing tumors, *see* androgen-producing ovarian tumors
visfatin, 92
visuo-spatial processing, 147

wigs and hairpieces, 17
Women's Health Initiative, 152

zidovudine, 172
zinc deficiency, and hair loss, 14

© in this web service Cambridge University Press www.cambridge.org